SCHEMBL3556211

SCHEMBL3556211

CCCc1ccc(S(=O)(=O)Nc2ccccc2OCCOc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.59
SLC16A3 O15427 2/20 0.50
CACNA1H O95180 2/20 0.50
CACNA1B Q00975 2/20 0.50
METAP2 P50579 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
MCL1 Q07820 1/20 0.49
BCL2A1 Q16548 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
WDR5 P61964 2/20 0.48
LIMK2 P53671 2/20 0.48
POLB P06746 1/20 0.47
PKM P14618 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561187 0.94 TDP1 (0.57) TDP1SLC16A3CACNA1HCACNA1BMETAP2
SCHEMBL3558807 0.92 TDP1 (0.56) TDP1SLC16A3CACNA1HCACNA1BMETAP2
SCHEMBL3558860 0.92 WDR5 (0.57) TDP1SLC16A3CACNA1HCACNA1BWDR5
SCHEMBL3554984 0.90 PKM (0.56) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3554494 0.88 PKM (0.56) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3565335 0.87 CACNA1H (0.53) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3552318 0.87 GFER (0.56) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3562888 0.87 SLC16A3 (0.64) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3561665 0.86 CACNA1H (0.58) TDP1SLC16A3CACNA1HCACNA1BHDAC3
SCHEMBL3563406 0.86 CACNA1H (0.52) TDP1SLC16A3CACNA1HCACNA1BHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 TDP1 2267/4885SLC16A3 425/4885CACNA1H 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.